SHUSMA KARKI: Open Payments
NPI 1679022370 · CATONSVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$966 in 44 payments from 13 companies in 2025. Trend: 2023 $532 · 2024 $1,050 · 2025 $966
Food & beverage: $966
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $181 |
| Astellas Pharma US Inc | 4 | $108 |
| Merck Sharp & Dohme LLC | 4 | $95 |
| AstraZeneca Pharmaceuticals LP | 3 | $95 |
| ABBVIE INC. | 4 | $94 |
| Lilly USA, LLC | 4 | $73 |
| PFIZER INC. | 4 | $67 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $66 |
| GlaxoSmithKline, LLC. | 3 | $63 |
| Abbott Laboratories | 2 | $41 |
Products named: Ozempic, Veozah, QULIPTA, MOUNJARO, Kerendia, FREESTYLE LIBRE 3, PAXLOVID, BREZTRI.
Industry payments across MD — which companies pay providers there.
